Results 191 to 200 of about 65,998 (238)

Adverse drug reaction assessment of pembrolizumab and nivolumab in esophageal cancer treatment based on the US FAERS database. [PDF]

Front Immunol
Chen J, Xu Q, Ying Y, Yu J, Liu Y, Zhao F, Shu Q.   +6 more
europepmc   +1 more source

Lack of Differences in the Pharmacokinetics of Therapeutic Monoclonal Antibodies Between Japanese and Non‐Japanese Individuals

The Journal of Clinical Pharmacology, Volume 66, Issue 8, August 2026.
Abstract Evaluation of the pharmacokinetics (PK) of new drugs in Japanese individuals is regularly requested by the Japanese regulatory agency prior to participation in global clinical trials or for bridging approaches for regulatory approval. However, the need for PK assessments in the Japanese population may be less compelling for monoclonal ...
Paridhi Gupta, Ashish Sharma, Bernd Meibohm   +2 more
wiley   +1 more source

Phase II trial of combination radiation, hormone, and immunotherapy in grade group 5 prostate cancer. [PDF]

J Immunother Cancer
Bryant JM, Sandoval M, Putney R, Trivedi P, Katende EN, Fink A, Naqvi SM, Kim Y, Yin V, Zhang J, Park JY, Serna A, Lam N, Pow-Sang J, Poch M, Li R, Manley BJ, Naghavi A, Torres-Roca J, Grass GD, Kim S, Latifi K, Hunt D, Johnstone P, Dhillon J, Rodriguez PC, Jain R, Fernandez DC, Yamoah K.   +28 more
europepmc   +1 more source

A Prospective Observational Study of Anamorelin During Chemoimmunotherapy in Non‐Small Cell Lung Cancer With Cachexia (SPIRAL‐ANA)

Journal of Cachexia, Sarcopenia and Muscle, Volume 17, Issue 4, August 2026.
ABSTRACT Background The prognosis of patients with advanced non‐small cell lung cancer (NSCLC) complicated by cancer cachexia remains poor. Anamorelin, a ghrelin receptor agonist, has been approved only in Japan for the treatment of cancer cachexia.
Kenji Morimoto, Junji Uchino, Makoto Hibino, Yuki Takeyasu, Ken Yamamoto, Yoshie Morimoto, Yusuke Chihara, Takayuki Nakano, Hiroyasu Kaneda, Shunya Tanaka, Shinsuke Ogusu, Yasuhiro Goto, Takashi Nomizo, Takayo Ota, Hiroaki Tsukamoto, Yoshizumi Takemura, Katsumi Nakatomi, Hayato Koba, Kohei Yoshimine, Takayuki Shimose, Tadaaki Yamada, Koichi Takayama   +21 more
wiley   +1 more source

Long-term complete remission of metastatic combined hepatocellular-cholangiocarcinoma with nivolumab following failure of targeted therapies: a case report. [PDF]

Front Oncol
Hong YM.
europepmc   +1 more source

Adjuvant Therapy for High-Risk Stage II Cutaneous Melanoma: Insights and Future Directions. [PDF]

Cancers (Basel)
Pravisano F, Costa J, Marchi L, Pascoletti G, Poletto E, Del Vecchio M, Spagnoletti A, Cimminiello C, Papadopoulos N, Pigozzo J, Piccin L, Roccuzzo G, Fava P, Puglisi F, Aprile G, Minisini AM.   +15 more
europepmc   +1 more source

Efficacy of Ipilimumab and Nivolumab Rechallenge in a Long-Term Melanoma Survivor: A Case Report. [PDF]

Am J Case Rep
Vromans AM, Constantinou M.
europepmc   +1 more source

Predictive Value of Insertion/Deletion Rate in Patients With Gastric Cancer Treated With Nivolumab Plus Chemotherapy. [PDF]

J Gastric Cancer
Kim HD, Lee H, Lee SY, Lee Y, Hyung J, Moon M, Shin J, Park YS, Ryu MH.   +8 more
europepmc   +1 more source